Difference between revisions of "Nivolumab and relatlimab (Opdualag)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the NCI Drug Dictionary: A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune...") |
m (Jwarner moved page Relatlimab (BMS-986016) to Nivolumab and relatlimab (Opdualag): FDA approval) |
(No difference)
| |
Revision as of 21:53, 22 March 2022
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth.
Preliminary data
Melanoma
- RELATIVITY-047: Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. link to original article contains verified protocol PubMed NCT03470922